A polygenic risk score for multiple myeloma risk prediction.

Genetic Predisposition to Disease Genome-Wide Association Study Humans Multiple Myeloma / diagnosis Polymorphism, Single Nucleotide Risk Factors

Journal

European journal of human genetics : EJHG

ISSN: 1476-5438

Titre abrégé: Eur J Hum Genet

Pays: England

ID NLM: 9302235

Informations de publication

Date de publication:
04 2022

Historique:

received: 25 03 2020

accepted: 08 10 2021

revised: 04 10 2021

pubmed: 1 12 2021

medline: 12 4 2022

entrez: 30 11 2021

Statut: ppublish

Résumé

There is overwhelming epidemiologic evidence that the risk of multiple myeloma (MM) has a solid genetic background. Genome-wide association studies (GWAS) have identified 23 risk loci that contribute to the genetic susceptibility of MM, but have low individual penetrance. Combining the SNPs in a polygenic risk score (PRS) is a possible approach to improve their usefulness. Using 2361 MM cases and 1415 controls from the International Multiple Myeloma rESEarch (IMMEnSE) consortium, we computed a weighted and an unweighted PRS. We observed associations with MM risk with OR = 3.44, 95% CI 2.53-4.69, p = 3.55 × 10

Identifiants

DOI: 10.1038/s41431-021-00986-8 PMID: 34845334 PMC: PMC8991223

pubmed: 34845334

doi: 10.1038/s41431-021-00986-8

pii: 10.1038/s41431-021-00986-8

pmc: PMC8991223

doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

474-479

Informations de copyright

Références

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

doi: 10.3322/caac.21492

Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362–9.

doi: 10.1056/NEJMoa054494

Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378:241–9.

doi: 10.1056/NEJMoa1709974

Agarwal A, Ghobrial IM. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. Clin Cancer Res. 2013;19:985–94.

doi: 10.1158/1078-0432.CCR-12-2922

Broderick P, Chubb D, Johnson DC, Weinhold N, Försti A, Lloyd A, et al. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nat Genet. 2011;44:58–61.

doi: 10.1038/ng.993

Martino A, Sainz J, Buda G, Jamroziak K, Reis RM, García-Sanz R, et al. Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review). Int J Oncol. 2012;40:625–38.

pubmed: 22159523

Chubb D, Weinhold N, Broderick P, Chen B, Johnson DC, Försti A, et al. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nat Genet. 2013;45:1221–5.

doi: 10.1038/ng.2733

Weinhold N, Johnson DC, Chubb D, Chen B, Försti A, Hosking FJ, et al. The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat Genet. 2013;45:522–5.

doi: 10.1038/ng.2583

Erickson SW, Raj VR, Stephens OW, Dhakal I, Chavan SS, Sanathkumar N, et al. Genome-wide scan identifies variant in 2q12.3 associated with risk for multiple myeloma. Blood. 2014;124:2001–3.

doi: 10.1182/blood-2014-07-586701

Campa D, Martino A, Varkonyi J, Lesueur F, Jamroziak K, Landi S, et al. Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. Int J Cancer. 2015;136:E351–358.

doi: 10.1002/ijc.29101

Campa D, Martino A, Macauda A, Dudziński M, Suska A, Druzd-Sitek A, et al. Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study. Leuk Lymphoma. 2019;60:1803–11.

doi: 10.1080/10428194.2018.1551536

Macauda A, Castelli E, Buda G, Pelosini M, Butrym A, Watek M, et al. Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients. Br J Haematol. 2018;183:375–84.

doi: 10.1111/bjh.15521

Martino A, Campa D, Buda G, Sainz J, García-Sanz R, Jamroziak K, et al. Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case-control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium. Leukemia. 2012;26:1419–22.

doi: 10.1038/leu.2011.352

Swaminathan B, Thorleifsson G, Jöud M, Ali M, Johnsson E, Ajore R, et al. Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma. Nat Commun. 2015;6:7213.

doi: 10.1038/ncomms8213

Mitchell JS, Li N, Weinhold N, Försti A, Ali M, van Duin M, et al. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nat Commun. 2016;7:12050.

doi: 10.1038/ncomms12050

Halvarsson B-M, Wihlborg A-K, Ali M, Lemonakis K, Johnsson E, Niroula A, et al. Direct evidence for a polygenic etiology in familial multiple myeloma. Blood Adv. 2017;1:619–23.

doi: 10.1182/bloodadvances.2016003111

Went M, Sud A, Försti A, Halvarsson B-M, Weinhold N, Kimber S, et al. Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Nat Commun. 2018;9:3707.

doi: 10.1038/s41467-018-04989-w

Pertesi M, Vallée M, Wei X, Revuelta MV, Galia P, Demangel D, et al. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma. Leukemia. 2019;33:2324–30.

doi: 10.1038/s41375-019-0452-6

Wei X, Calvo-Vidal MN, Chen S, Wu G, Revuelta MV, Sun J, et al. Germline lysine-specific demethylase 1 (LSD1/KDM1A) mutations confer susceptibility to multiple myeloma. Cancer Res. 2018;78:2747–59.

doi: 10.1158/0008-5472.CAN-17-1900

Went M, Sud A, Speedy H, Sunter NJ, Försti A, Law PJ, et al. Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. Blood Cancer J. 2018;9:1.

doi: 10.1038/s41408-018-0162-8

Pertesi M, Went M, Hansson M, Hemminki K, Houlston RS, Nilsson B. Genetic predisposition for multiple myeloma. Leukemia. 2020;34:697–708.

doi: 10.1038/s41375-019-0703-6

Burton H, Chowdhury S, Dent T, Hall A, Pashayan N, Pharoah P. Public health implications from COGS and potential for risk stratification and screening. Nat Genet. 2013;45:349–51.

doi: 10.1038/ng.2582

Hsu L, Jeon J, Brenner H, Gruber SB, Schoen RE, Berndt SI, et al. A model to determine colorectal cancer risk using common genetic susceptibility loci. Gastroenterology. 2015;148:1330–9.e14.

doi: 10.1053/j.gastro.2015.02.010

Lecarpentier J, Silvestri V, Kuchenbaecker KB, Barrowdale D, Dennis J, McGuffog L, et al. Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores. J Clin Oncol. 2017;35:2240–50.

doi: 10.1200/JCO.2016.69.4935

Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nat Rev Genet. 2018;19:581–90.

doi: 10.1038/s41576-018-0018-x

Seibert TM, Fan CC, Wang Y, Zuber V, Karunamuni R, Parsons JK, et al. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. BMJ. 2018;360:j5757.

doi: 10.1136/bmj.j5757

Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, et al. Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. Am J Hum Genet. 2019;104:21–34.

doi: 10.1016/j.ajhg.2018.11.002

Galeotti AA, Gentiluomo M, Rizzato C, Obazee O, Neoptolemos JP, Pasquali C, et al. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. J Med Genet. 2021;58:369–77.

doi: 10.1136/jmedgenet-2020-106961

Halvarsson B-M, Wihlborg A-K, Ali M, Lemonakis K, Johnsson E, Niroula A, et al. Direct evidence for a polygenic etiology in familial multiple myeloma. Blood Adv. 2017;1:619–23.

doi: 10.1182/bloodadvances.2016003111

Du Z, Weinhold N, Song GC, Rand KA, Van Den Berg DJ, Hwang AE, et al. A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Blood Adv. 2020;4:181–90.

doi: 10.1182/bloodadvances.2019000491

Rajkumar SV. Updated diagnostic criteria and staging system for multiple myeloma. Am Soc Clin Oncol Educ Book. 2016;35:e418–23.

doi: 10.1200/EDBK_159009

Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos M-V, et al. Multiple myeloma. Nat Rev Dis Prim. 2017;3:17046.

doi: 10.1038/nrdp.2017.46